

2024 AACT Symposium
Antidote Shortages: Impact & Response
April 10, 2024 | Washington, DC

Activity Overview

This half-day symposium gathers experts, researchers, healthcare professionals, and policymakers committed to addressing the critical issue of antidote shortages in our healthcare system. Attendees will engage in insightful discussions on the root causes and far-reaching consequences of these shortages, examining their effects on patient care, healthcare economics, and public health. Furthermore, the symposium will spotlight cutting-edge solutions and collaborative approaches aimed at mitigating these shortages, fostering resilience in healthcare systems, and ensuring timely access to life-saving antidotes. Together, participants will work towards building a more robust and responsive healthcare infrastructure that can effectively combat antidote shortages and safeguard patient well-being.

Target Audience

This activity is designed for an audience of physicians, pharmacists and nurses.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

Stocking Guidelines for Antidotes - Which Ones Are Truly Essential?

- Discuss how to determine what makes an antidote essential.
- Discuss data surrounding decision making for determining if an antidote is essential.

Ethical Issues in Antidote Administration During Shortages - What Are Some Best Practices?

- Describe ethical and medicolegal considerations surrounding medication distribution during times of shortage.
- Identify best practices to permit ethical distribution of medications in limited supply.

The Institutional Response: What Can You Do Locally to Address Antidote Shortages?

- Describe how an institution can respond to drug shortages.
- Discuss how you can be involved in drug shortages.

Expired Medications: Dead to Me or Just Dated?

- Explore the origins of expiry dating.
- Explore regulatory barriers to utilization of expired medications.

How Well Do We Do with Antidote Shortages?

- List 2 antidote shortages that resulted in the use of alternative therapies.
- Summarize data to support alternative therapy use during antidote shortages.

Antidote Shortage Outcomes and Solutions from the ToxIC Registry

- Explain the need for antidotal shortage outcome and solution tracking.
- Discuss antidotal shortage subregistry findings 14 months after subregistry implementation.

Use of Artificial Intelligence: Can AI Provide the Answers We Want?

- Discuss current trends in AI regarding antidote shortage and stocking.
- Identify the shortcomings and advantages of AI in this space.

The FDA's Response to Mitigating Antidote Shortages

- Describe FDA's role in addressing and preventing drug shortages.
- Discuss specific shortages of antidotes and FDA's actions to mitigate them.

Criteria for Success

Statements of credit will be awarded based on the participant's attendance. A statement of credit will be available upon completion of an online evaluation/claim credit form available at:

https://education.acmt.net/p/2024-aact-symposium-CE#tab-product_tab_instructions

Please claim your credit by April 30, 2024.

If you have questions about this CE activity, please contact AKH Inc at JGoldman@akhcme.com.



CE credit provided by AKH Inc., Advancing Knowledge in Healthcare.



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



IPCE CREDIT™

This activity was planned by and for the healthcare team, and learners will receive 5.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physicians

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 5.0 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists

AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 5.0 contact hours.

Nurses

Credit being awarded: 5.0 ANCC contact hours

Commercial Support

There is no commercial support for this activity.

DISCLOSURES

Name	Relationship	Commercial Interest
Maryann Amirshahi, PharmD, MD, MPH, PhD, FACMT (faculty; planner/reviewer)	N/A	Nothing to disclose
Brenna Farmer, MD, MBA, MS (faculty)	N/A	Nothing to disclose
Valerie E. Jensen, CAPT (Ret.), RPh (faculty)	N/A	Nothing to disclose
Jeanna Marraffa, PharmD, MPH, DABAT (faculty)	N/A	Nothing to disclose
Nikolaus Matsler, MD (faculty)	N/A	Nothing to disclose
Renee Petzel Gimbar, PharmD (faculty)	Researcher	Xeris Pharmaceuticals
Silas W. Smith, MD (faculty)	N/A	Nothing to disclose
James Whitledge, MD (faculty)	N/A	Nothing to disclose
Dorothy Caputo, MA, BSN, RN - VP, Healthcare Continuing Education and Operations	N/A	Nothing to disclose
Michele Bielarski, RN (planner/reviewer)	N/A	Nothing to disclose
AKH Inc Staff and Planners	N/A	Nothing to disclose
ACMT Staff and Planners	N/A	Nothing to disclose
All of the relevant financial relationships listed for these individuals have been mitigated.		

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course

serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.com with your information with "Opt Out" in the subject line.